ASX - Delayed Quote AUD

Melodiol Global Health Limited (ME1.AX)

0.0030 -0.0010 (-25.00%)
At close: April 26 at 4:10 PM GMT+10
Key Events
Loading Chart for ME1.AX
DELL
  • Previous Close 0.0040
  • Open 0.0030
  • Bid 0.0030 x --
  • Ask 0.0030 x --
  • Day's Range 0.0030 - 0.0030
  • 52 Week Range 0.0030 - 0.4400
  • Volume 1,500,247
  • Avg. Volume 8,141,774
  • Market Cap (intraday) 845,610
  • Beta (5Y Monthly) 2.55
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6000
  • Earnings Date Feb 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser. In addition, the company develops Halucenex, which is in phase II clinical trials, which will test the efficacy of psilocybin on treatment of resistant Post Traumatic Stress Disorder. Further, it engages in marketing of its hemp based food, feed supplements, and topical products; manufacture and sale of packaged consumer products; conducts clinical trial and development of synthetic psilocybin micro and macro dose formulations to treat treatment resistant depression and anxiety; and development of psychedelic medicines. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

melodiolglobalhealth.com

--

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: ME1.AX

Performance Overview: ME1.AX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ME1.AX
92.50%
S&P/ASX 200 [XJO]
0.20%

1-Year Return

ME1.AX
98.50%
S&P/ASX 200 [XJO]
3.55%

3-Year Return

ME1.AX
99.92%
S&P/ASX 200 [XJO]
7.53%

5-Year Return

ME1.AX
99.97%
S&P/ASX 200 [XJO]
18.64%

Compare To: ME1.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ME1.AX

Valuation Measures

Annual
As of 4/28/2024
  • Market Cap

    8.76M

  • Enterprise Value

    17.71M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.16

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.94

  • Enterprise Value/EBITDA

    -0.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -277.18%

  • Return on Assets (ttm)

    -33.31%

  • Return on Equity (ttm)

    -389.56%

  • Revenue (ttm)

    18.92M

  • Net Income Avi to Common (ttm)

    -35.52M

  • Diluted EPS (ttm)

    -0.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    692k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    8.37M

Company Insights: ME1.AX

People Also Watch